BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Recruiting · Phase 1 · NCT06120283
Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
At a glance
- Research payments reported, 2025
- $793,503
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 433
About the trial
- Sponsor
- BeOne Medicines
- Tested
- BGB-43395 (drug), Fulvestrant (drug), Letrozole (drug), Elacestrant (drug), Anti-Diarrheal Agent (drug)
- Dates
- Started 2023-12-01; completion 2029-12
- Results posted
- Not yet
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.
From ClinicalTrials.gov, last updated 2026-10-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $793,503 in research payments for this study in 2025 (59 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alexander Philipovskiy, M.D., PH.D Medical Oncology · Sanford, FL
- Wasif M. Saif, MD Hematology & Oncology · Detroit, MI
- Katherine K. Clifton, MD Medical Oncology · Saint Louis, MO
- Carey K. Anders, M.D. Medical Oncology · Chapel Hill, NC
- Robert Wesolowski, MD Medical Oncology · Columbus, OH
- Shiraj Sen, M.D. Hematology & Oncology · Irving, TX
- Timothy A. Yap, MD Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $347,980
- Next Oncology $127,636
- Florida Cancer Specialist (scri) - Fort Myers $107,258
- The Ohio State University Dba: Comprehensive Canc $104,063
- Washington University $45,927
- Duke University , $43,734
- Karmanos Cancer Center, MI $16,905
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.